Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3092 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2019-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cbffbdc951a8828fa9dff04c620683d |
publicationDate |
2021-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
BR-112020025476-A2 |
titleOfInvention |
METHODS FOR TREATING CANCER WITH ANTI-CD3XMUC16 BISPECIFIC ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
abstract |
METHODS FOR TREATING CANCER WITH BISPECIFIC ANTI-CD3XMUC16 ANTIBODIES AND ANTI-PD-1 ANTIBODIES ”. The present invention relates to methods comprising administering to an individual in need of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to the programmed death receptor 1 (PD-1) in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to Mucine 16 (MUC16) and CD3. |
priorityDate |
2018-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |